What does agenus inc. — financial royalty assets, allowance mean?

This metric represents the cumulative valuation adjustments, such as allowances for credit losses or impairment reserves, applied to the royalty assets linked to Agenus Inc. It reflects management's assessment of potential risks or declines in the expected future cash flows from these specific licensed products. A significant change in this allowance can signal shifts in the commercial outlook or credit risk profile of the underlying pharmaceutical programs.

Ligand Pharmaceuticals LGND Agenus Inc. — Financial Royalty Assets, Allowance

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

WECValuation Allowances And Reserves Charged To Cost And Expense

$35.7M+36.1%

NOVRoyalty — Contract With Customer Receivable After Allowance For Credit Loss

$43M+231%

ABRAgency Business — Allowance for loss-sharing obligations

$106.77M+24.9%

SSNCValuation Allowances And Reserves Charged To Cost And Expense

$4.65M+20.8%

OGS

OGSAllowance for Doubtful Accounts

$14.6M-12.6%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's agenus inc. — financial royalty assets, allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's agenus inc. — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported agenus inc. — financial royalty assets, allowance of $408K in Q1 2026.
What does agenus inc. — financial royalty assets, allowance mean?: This metric represents the cumulative valuation adjustments, such as allowances for credit losses or impairment reserves, applied to the royalty assets linked to Agenus Inc. It reflects management's assessment of potential risks or declines in the expected future cash flows from these specific licensed products. A significant change in this allowance can signal shifts in the commercial outlook or credit risk profile of the underlying pharmaceutical programs.